Deals this week: Causeway Sensors, Ampersand Capital Partners, UroCure

23 March 2018 (Last Updated March 26th, 2018 11:13)

Causeway Sensors Ltd has raised £1.5m ($2.09m) through a financing round led by the Bank of Ireland Kernel Capital Growth Fund in syndication with other private investors.

Causeway Sensors Ltd has raised £1.5m ($2.09m) through a financing round led by the Bank of Ireland Kernel Capital Growth Fund in syndication with other private investors. Kernel Capital invested £1.2m ($1.68m) in the transaction.

Based in the UK, Causeway Sensors is a diagnostics company that develops and manufactures sensing packages and consumable biochips.

The company plans to use the funds to develop technology and explore new markets.

Private equity firm Ampersand Capital Partners has invested funds in Nexcelom Bioscience LLC.

Nexcelom is a provider of cell counters and image cytometry products for biomedical research and the biopharma industry. The company plans to use the proceeds towards its global growth initiatives.

Both the companies involved in the transaction are based in the US.

US-based medical device company UroCure LLC has raised $1.3m through a venture financing round.

The company plans to use the funds for the development of urethral slings that are designed to treat female stress urinary incontinence.

“Corindus plans to use the funds from the offering for general corporate purposes, including global commercialisation of its CorPath GRX System.”

Corindus Vascular Robotics Inc has raised $25m through the private placement of 20 million shares of its common stock priced at $1.25 a share. The offering will be subscribed to by a select group of existing and new investors.

The company concurrently plans to issue warrants to purchase an aggregate of 0.875 million shares of common stock priced at $1.4 a share.

Corindus plans to use the funds from the offering for general corporate purposes, including global commercialisation of its CorPath GRX System.

Based in the US, Corindus Vascular Robotics is a developer of robotics systems for interventional vascular procedures.

Akers Biosciences Inc has raised $0.048m through the private placement of 260,000 shares of its common stock priced at $0.1875 a share.

Based in the US, Akers is a provider of rapid screening and testing products.

Righton has signed a licensing agreement for the distribution of Akonni Biosystems Inc’s products in China.

Righton will promote sales of Akonni Biosystems’ TruTip technology and commercialise the TruDiagnosis system.

The agreement also provides Akonni with exclusive rights to Righton’s molecular diagnostic products outside China.

Based in China, Righton is an in vitro diagnostics company, while Akonni is a molecular diagnostics company based in the US.